<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Delgado-Calle J</submitter><funding>BLRD VA</funding><funding>NHLBI NIH HHS</funding><funding>National Institutes of Health</funding><funding>NIAMS NIH HHS</funding><funding>U.S. Department of Veterans Affairs</funding><pagination>2878-2890</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5901377</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>32(5)</volume><pubmed_abstract>Parathyroid hormone (PTH) affects the skeleton by acting on osteocytes (Ots) in bone through yet unclear mechanisms. We report that matrix metalloproteinase 14 (MMP14) expression/activity are increased in bones from mice with genetic constitutive activation (ca) of the PTH receptor 1 (PTH1R) in Ots (caPTH1ROt) and in bones from mice exposed to elevated PTH levels but not in mice lacking [conditional knockout (cKO)] the PTH1R in Ots (cKOPTH1ROt). Furthermore, PTH upregulates MMP14 in human bone cultures and in Ot-enriched bones from floxed control mice but not from cKOPTH1ROt mice. MMP14 activity increases soluble receptor activator of NF-κΒ ligand production, which in turn, stimulates osteoclast differentiation and resorption. Pharmacologic inhibition of MMP14 activity reduced the high bon</pubmed_abstract><journal>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</journal><pubmed_title>MMP14 is a novel target of PTH signaling in osteocytes that controls resorption by regulating soluble RANKL production.</pubmed_title><pmcid>PMC5901377</pmcid><funding_grant_id>R01 AR059357</funding_grant_id><funding_grant_id>I01 BX002104</funding_grant_id><funding_grant_id>1 101 BX002104‐01</funding_grant_id><funding_grant_id>T35 HL110854</funding_grant_id><funding_grant_id>R01‐AR060332</funding_grant_id><funding_grant_id>R01‐AR059357</funding_grant_id><funding_grant_id>R01 AR060332</funding_grant_id><pubmed_authors>Sanudo C</pubmed_authors><pubmed_authors>Hancock B</pubmed_authors><pubmed_authors>Riancho JA</pubmed_authors><pubmed_authors>Tonra JR</pubmed_authors><pubmed_authors>Delgado-Calle J</pubmed_authors><pubmed_authors>McAndrews K</pubmed_authors><pubmed_authors>Bellido T</pubmed_authors><pubmed_authors>Bruzzaniti A</pubmed_authors><pubmed_authors>Likine EF</pubmed_authors><pubmed_authors>Sato AY</pubmed_authors></additional><is_claimable>false</is_claimable><name>MMP14 is a novel target of PTH signaling in osteocytes that controls resorption by regulating soluble RANKL production.</name><description>Parathyroid hormone (PTH) affects the skeleton by acting on osteocytes (Ots) in bone through yet unclear mechanisms. We report that matrix metalloproteinase 14 (MMP14) expression/activity are increased in bones from mice with genetic constitutive activation (ca) of the PTH receptor 1 (PTH1R) in Ots (caPTH1ROt) and in bones from mice exposed to elevated PTH levels but not in mice lacking [conditional knockout (cKO)] the PTH1R in Ots (cKOPTH1ROt). Furthermore, PTH upregulates MMP14 in human bone cultures and in Ot-enriched bones from floxed control mice but not from cKOPTH1ROt mice. MMP14 activity increases soluble receptor activator of NF-κΒ ligand production, which in turn, stimulates osteoclast differentiation and resorption. Pharmacologic inhibition of MMP14 activity reduced the high bon</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 May</publication><modification>2025-05-29T22:17:38.326Z</modification><creation>2025-05-29T22:17:38.326Z</creation></dates><accession>S-EPMC5901377</accession><cross_references><pubmed>29401593</pubmed><doi>10.1096/fj.201700919RRR</doi><doi>10.1096/fj.201700919rrr</doi></cross_references></HashMap>